A look at the beleaguered offshore drilling industry, specifically two companies who had different strategies during the better times, and why investors shouldn't forget about this industry. Read More
Scott Chan moved from China to the U.S. with family at the age of ten. He passed the rigorous entrance exam and attended the merit-based Stuyvesant High School, widely held to be best public school in New York City. He earned undergraduate degrees from New York University followed by an MBA degree from the Zicklin School of Business at Baruch College.
Shortly thereafter Scott partnered with Dr. Stephen Leeb on numerous financial publications. Today, he serves as the lead analyst for Real World Investing and The Complete Investor.
Mr. Chan is an avid baseball fan and enjoys outdoor activities in his spare time. A multicultural person, he reads Chinese and speaks fluent Mandarin and Cantonese Chinese.
Analyst Articles
Heading into this week’s Federal Open Market Committee meeting, most expected another rate hike, and the Fed delivered. With one dissenter, the committee voted to up the target federal funds rate to a range of 1 to 1.25 percent. This marks the fourth quarter-percentage point rate increase since the Financial… Read More
On Wednesday, we recommended buying to open the PowerShares DB US Dollar Index Bullish Fund (NYSE: UUP) December 15, 2017 $25 call option. Our dollar indicator became bullish enough to warrant going long the dollar. At the same time, we recommended buying to close the CurrencyShares Japanese Yen Trust… Read More
Sell to close the CurrencyShares Japanese Yen Trust (NYSE: FXY) July 21, 2017 $90 call option. Buy to open the PowerShares DB U.S. Dollar Index Bullish Fund (NYSE: UUP) December 15, 2017 $25 call option. We suggest paying no more than 60 cents per contract. We… Read More
Neither miner nor ETF, Franco-Nevada offers the attractive qualities of both. Read More
Biotech Theravance Biopharma (Nasdaq: TBPH) this week reported another piece of good clinical data. The company reported that multiple studies conducted on VIBATIV—currently its only marketed drug—showed superior in vitro potency for VIBATIV against the S. aureus pathogens compared to other commercially available antibiotics. VIBATIV is already approved to treat S. aureus, but the company hopes the studies will differentiate it from competing antibiotics. Read More
Yesterday we recommended buying to open a position in the CurrencyShares Japanese Yen ETF (NYSE: FXY) July 21, 2017 $90 call option, at a suggested limit price of 55 cents. As noted in the Trade Alert, this is not an indicator-based trade. The trade is intended as a short-term hedge… Read More
Investor activism can be a positive by shaking things up at a struggling company and holding incumbent management accountable. Read More
After a weak March, then a strong April, U.S. hiring activity again fell lower than expected in May. Today’s Labor Department monthly report shows that non-farm payrolls only increased by 138,000, well below the 182,000 consensus economist projection. Furthermore, the estimates for March and April were revised downward by a… Read More
By far, the gold and gold stocks indicators are our most bearish indicators right now. Our gold stocks indicator has actually become even more bearish, and our VanEck Vectors Gold Miners ETF (GDX) December 23 put is still a “buy” for readers who may have missed the original… Read More